Clodronate disodium (dichloromethylene diphosphonate), a specific inhibitor of bone resorption, was given by mouth (1-0-3-2 g daily) to nine patients with primary hyperparathyroidism for two to 32 weeks so that its clinical and metabolic effects could be evaluated. Bone resorption decreased in all patients as judged by a fall in the fasting urinary calcium to creatinine and hydroxyproline to creatinine ratios. Serum calcium concentration was increased in all patients before treatment and fell in response to treatment to values near the upper end of the normal range. Hypercalcaemia and hypercalciuria recurred when treatment was stopped.
Introduction
The usual and preferred treatment of symptomatic primary hyperparathyroidism is by surgical removal of the parathyroid adenoma or hyperplastic glands. In mild, asymptomatic cases, however, particularly in the elderly or unfit, the role of surgery is controversial.' 2 In such patients it is often uncertain whether symptoms, such as dyspepsia, or signs, such as hypertension, are related to the increased plasma calcium concentration. In some patients it may be advantageous to reduce the serum calcium concentration by medical management so that the indications for surgery may be assessed. In other patients with appreciable hypercalcaemia, who are unfit for surgery or in whom the diagnosis is not immediately clear, reducing the serum calcium concentration and improving the patient's general condition confer obvious advantages.
There are several approaches to the-medical management of hypercalcaemia, which may include administration of oral phosphate and, in acute crises, repletion of extracellular fluid volume.3 4 [12] [13] [14] and in primary hyperparathyroidism.'5 Our own preliminary findings using clodronate in four patients with primary hyperparathyroidism'0 encouraged us to extend these observations to a larger number of patients studied for longer periods.
Patients and methods
The effects of treatment with clodronate were studied in nine patients aged 61-72 years with primary hyperparathyroidism (table I) . Complications of hyperparathyroidism in these patients included renal calculi (three patients), skeletal pain (three), and constipation and nocturia (one).
No patient was receiving thiazide diuretics, and only one (case 7) was judged to be dehydrated. This patient was treated for three days with infusions of sodium chloride before study. All patients had normal renal function (plasma creatinine concentration less than 120 ismol/l (14 mg/100 ml)) and biochemical evidence of hyperparathyroidism as judged by sustained hypercalcaemia, a low serum phosphate concentration, and decreased tubular reabsorption of phosphate. Immunoreactive parathyroid hormone was detectable in serum in all patients, the values being either in the normal range or raised. Five patients underwent successful parathyroidectomy after completion of the study. One patient (case 5) was admitted to the study because of recurrence of hypercalcaemia after previous surgery for parathyroid hyperplasia.
Urine and blood were collected at intervals of one to seven days for biochemical determinations before and during treatment. Blood was taken after an overnight fast and serum separated for determination of calcium, phosphate, and creatinine concentrations, alkaline phosphatase activity, albumin concentration, and liver transaminase activities (Technicon SMAC). Serum was also stored at -200C for subsequent analysis of immunoreactive parathyroid hormone. Haematological tests (haemoglobin concentration, white cell count, and platelet count) were performed with a Technicon Haemalog 8.
After an overnight fast patients emptied their bladders and then collected urine for the next two hours ("fasting urine"). The urine produced over the subsequent 22 hours was collected separately. Urine measurements included calcium, phosphate, and creatinine concentrations (Technicon SMAC). Urinary excretion of peptidebound hydroxyproline was measured by a modification of Stegemann's method.'6 Renal tubular reabsorption of phosphate was calculated as the ratio of maximal tubular reabsorption of phosphate to glomerular filtration rate. '7 Urinary excretion of hydroxyproline was expressed as a ratio to the creatinine concentration in urine. Calcium excretion was expressed as mmol calcium/l glomerular filtrate."8 Serum immunoreactive parathyroid hormone was assayed by an immunoradiometric method'9 with a guinea pig antiserum raised against bovine parathyroid hormone (code BW 211/42, provided by the Medical Research Council). Samples were assayed against a reference preparation of human parathyroid hormone (75/549) provided by the National Institute for Biological Standards and Control, and the assay procedure was fully automated with the Kemtek 3000 (Kemble Instrument Co, Burgess Hill, Sussex).
Clodronate (10-3-2 g daily) was given as a single dose before breakfast. If gastrointestinal side effects such as diarrhoea were noted it was administered in two or three divided doses throughout the day.
The significance of the difference between treatment periods was calculated with Student's t test for paired observations.
Results

CLINICAL RESPONSES
In two of the three patients with skeletal pain, this decreased during treatment. None of the three patients with a history of renal calculi had further loin pain, and no stones were passed during treatment, although the period of observation (two to 32 weeks) was insufficient to judge whether stone frequency decreased. A bladder stone was diagnosed during treatment in a further patient (case 9; table I) and subsequently removed by litholopaxy. One patient who was severely hypercalcaemic (serum calcium concentration 4-1 mmol/l (16-4 mg/100 ml)) remained hypercalcaemic after volume repletion and clodronate for two weeks (serum calcium concentration 3-55 mmol/l (14-2 mg/100 ml)), and he underwent successful parathyroidectomy for a single adenoma.
The drug was well tolerated with no detectable changes in hepatic, renal, or haematological function. The only side effect noted was mild gastrointestinal disturbance in one patient, which was controlled by dividing the daily dose of clodronate. treatment with clodronate (serum calcium concentration fell from 4-1 to 3 55 mmol/l (16 4 to 14-2 mg/100 ml)), when a parathyroid adenoma was removed.
The 24-hour urinary excretion of calcium was measured serially in four patients and fell from 8-02 VSEM 1-77 to 6 02 ±0 8 mmol/24 h (320 70 to 240 1-30 mg/24 h) during treatment. In contrast to the rapid and consistent fall in excretion of hydroxyproline the response of serum alkaline phosphatase activity varied. In three patients a fall in alkaline phosphatase activity occurred which was preceded by a "flare" (fig 2) . No consistent changes were observed in serum phosphate concentration or renal tubular reabsorption of phosphate.
After treatment with clodronate was stopped hypercalcaemia recurred and urinary excretion of both calcium and hydroxyproline rose towards pretreatment values (fig 1) . One patient (case 5) was given a second course of clodronate, which reversed these changes. In the three patients who were treated for 19 weeks or more serum and urinary calcium began to return towards pretreatment values.
Discussion
All nine patients studied showed evidence that clodronate suppressed bone resorption, as indicated by a fall in the urinary excretion of calcium and hydroxyproline into the normal range. Serum calcium concentration, however, fell generally only to the upper part of the normal range. The failure to suppress serum calcium concentration to normal despite a fall in fasting calcium excretion suggests that renal tubular resorption of calcium remained high in these patients,3 reflecting the continued secretion of parathyroid hormone despite treatment.
Net bone resorption was increased in all patients before treatment as judged by urinary excretion of calcium and hydroxyproline. The mechanism responsible for the fall in serum and urinary calcium probably includes drug-induced inhibition of bone resorption without inhibition of bone formation. This suggests that there is a temporary "uncoupling" between the rates of bone resorption and bone formation, which are usually closely linked, under both normal and abnormal conditions.20 With prolonged treatment, however, serum calcium concentration and urinary calcium excretion increased, suggesting that a recoupling of bone resorption and formation had taken place. The implications that the hypocalcaemic effect of clodronate relies on its ability to dissociate transiently mineral accretion from resorption suggests that clodronate might be of limited value in the long-term medical management of primary hyperparathyroidism, but more extensive work is required on a larger number of patients to determine whether the drug is of only short-term benefit.
These inhibitors of bone resorption may be useful not-nnly in treating patients who are unsuitable for surgery but in preparing patients with extensive bone disease for surgery. If bone disease is suppressed preoperatively the "hungry bone" syndrome, which produces postoperative hypocalcaemia,'1 may be avoided, leading to a safer and less troublesome postoperative recovery.
In the only other reported study of clodronate in primary hyperparathyroidism'5 the patients had milder disease than ours and were treated for shorter periods. None the less, a small but significant reduction in plasma calcium concentration occurred. The diphosphonate sodium etidronate, used to treat heterotopic ossification and Paget's disease,22 has been studied to only a limited extent. In the study by Kaplan et al23 sodium etidronate reduced urinary excretion of calcium and hydroxyproline but produced a significant reduction in serum calcium concentration in only two of the six patients studied. Our own preliminary observations with sodium etidronate suggest that it is less effective than clodronate in reducing the hypercalcaemia of hyperparathyroidism.
Our present observations therefore suggest that clodronate is a promising drug for at least the short-term medical management of hypercalcaemia in primary hyperparathyroidism. The results showed no linkage between the insulin gene and the inheritance of maturity onset diabetes of the young.
Introduction
The genetic basis of non-insulin dependent diabetes mellitus remains poorly understood. Although a high level of concordance exists in twin studies,' a clear pattern of inheritance has not emerged from family or linkage studies. One reason for this is the pronounced heterogeneity of the disease.2 A subgroup of non-insulin dependent diabetes in which genetic analysis might prove more fruitful was described by Tattersall and Fajans.3 4 This subgroup, referred to as "maturity onset diabetes in the young," is manifested by non-ketotic diabetes which develops in early adult life and persists with little progression and few complications, and it provides several advantages as a subgroup for genetic analysis. Firstly, it is inherited in a pattern consistent with an autosomal dominant trait; 5300 of siblings are affected and 85 % of patients have a parent with diabetes. This pattern of inheritance allows linkage studies to be performed within families using genetic markers. Secondly, because the disease is usually expressed at a young age it is often possible to analyse several generations of one family and avoid inaccuracies that result from failing to identify subjects who would later develop diabetes.
Results of linkage analysis of affected families with a wide range of genetic markers, including the HLA loci, have all been negative.' The cloning and sequencing of the insulin gene has, however, led to the discovery of a new marker, a highly variable length polymorphism adjacent to the 5' end of the insulin gene, which may be identified by restriction endonuclease gene mapping.8 Patients with maturity onset diabetes of the young often show both low insulin concentrations and a poor response of insulin to glucose challenge7 8; hence it is important to determine whether a locus in the region of the insulin gene is
